Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

NCT07217028 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

SCC - Squamous Cell Carcinoma
Radiotracer
Head and Neck Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Cetuximab (EGFR inhibitor)
DRUG: 18F-NOTA-ABY-030
PROCEDURE: Positron Emission Tomography (PET)

Sponsor

Vanderbilt-Ingram Cancer Center